BLCO
Bausch + Lomb Corporation·Healthcare
16.82
1.386%(+0.23)
Market ClosedLast Updated: — ET
52W L: $10.4552W H: $18.91
BLCO NEWS
businesswire.com
2d ago
Bausch + Lomb Reports Nearly 725,000 Pounds of Contact Lens, Lens Care and Eye Care Materials Collected and Recycled Through ONE By ONE Recycling Program
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its one-of-a-kind ONE by ONE Recycling program, created in collaboration with international recycling leader TerraCycle®, has collected and recycled a total of 119,715,074 units, or 724,922 pounds, of used contact lenses, eye care and lens care materials in the United States – the equivalent of about five backya.
defenseworld.net
Apr 10
Comparing Biodesix (NASDAQ:BDSX) & Bausch + Lomb (NYSE:BLCO)
Biodesix (NASDAQ: BDSX - Get Free Report) and Bausch + Lomb (NYSE: BLCO - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, institutional ownership and valuation. Insider and Institutional Ownership 21.0% of Biodesix shares
businesswire.com
Apr 6
Bausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual Meeting
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of new scientific data and events taking place during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, D.C., April 10-13, 2026. Forty-five presentations and posters will highlight the results of studies evaluating the company's broad portfolio of prod.
defenseworld.net
Mar 31
Bausch + Lomb Corporation (NYSE:BLCO) Receives Average Rating of “Hold” from Analysts
Shares of Bausch + Lomb Corporation (NYSE: BLCO - Get Free Report) have been given an average recommendation of "Hold" by the fifteen ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, ten have given a hold recommendation and four have given a buy
businesswire.com
Mar 30
Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 29, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the.
defenseworld.net
Mar 30
Bausch + Lomb Corporation (NYSE:BLCO) Short Interest Up 50.7% in March
Bausch + Lomb Corporation (NYSE: BLCO - Get Free Report) was the target of a large growth in short interest in March. As of March 13th, there was short interest totaling 4,006,617 shares, a growth of 50.7% from the February 26th total of 2,659,462 shares. Based on an average trading volume of 422,793 shares, the short-interest
